Cannevert Therapeutics

​​​​​​Michael J. A. Walker

President and Head of Biology


Michael Walker received training in pharmacology at the University of London UK which include a period of drug discovery at Pfizer Ltd. UK.  He also received a PhD from London after initial studies in Hong Kong.  His main interest has always been in the discovery of drugs (whether naturally occurring or not) and in the process of drug discovery itself.  His commitment has always had an academic base and in addition to 43 years at UBC has contributed to universities around the world.  However, a love of drug discovery has meant a commitment over the last 25 years to drug discovery, the founding of biotech companies, and leading searches for new drugs.  Altogether, he has been the founder or co-founder of 8 different drug discovery companies, both private and public.  Public companies include Cardiome Pharma (TSX:COM) in Canada and Verona Pharma Ltd in London (AIM:VRP), UK.  Private companies were founded principally for drug discovery purposes, but also include a contract research organization (Pneumolabs UK Ltd.).   In addition, he has been a director of other companies the most recent being IOMet which recently was acquired by a large pharma company.  Such activity has not impeded his academic research activities that have resulted in many publications, conference presentations, etc.  His driving force has always been drug discovery.  Most recently this has led to the recent foundation of Cannevert Therapeutics Ltd.; a company designed to create, and inact, a coherent and rational attempt to insert strict scientific rigour into the rational and proper therapeutic use of cannabis and its constituent cannabinoid molecules, as opposed to uses based upon anecdotes, presumptions and profit-seeking.